Ginkgo Q4 2024 revenue $44M (+26% YoY); net loss improves to $(108)M; 2025 rev guidance $160-180M

Ginkgo Bioworks Holdings, Inc.

2024-FY EPS reported -$10.54 revenue$227,043,000

Q4 total revenue $44M (up 26% YoY); Cell Engineering rev $35M (+29% YoY), Biosecurity $9M.
GAAP net loss $(108)M vs $(212)M in Q4 2023; Adj EBITDA $(57)M vs $(101)M.
Cash flow $(55)M in Q4, improved from $(114)M in Q3; cash balance $562M.
FY2025 guidance: total revenue $160-180M, Cell Engineering $110-130M, Biosecurity at least $50M.
Cost-cutting achieved $190M annualized run-rate savings; targeting $250M by Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.